Among the most followed stock market shares at present we of course find the Canopy Growth shares that we will examine here in detail.In this article we will in fact explain to you how to effectively trade in this asset through a thorough understanding of this company and thereby be capable of better anticipating its future trends through charts on this company’s share price.We will particularly reveal some key facts and figures relating to this group, details of its activities as well as its real time share price and useful information about its competitors and strategic alliances.You will thereby have everything you need to complete comprehensive analyses of Canopy Growth’s share price and take position judiciously.
General presentation of the Canopy Growth Company:
The Canadian group Canopy Growth is a specialist in the production and sale of medical cannabis.This company in facts markets different products from the culture of medical cannabis such as oils and concentrates as well as capsules and hemp.
The products sold by Canopy Growth have the main objective of naturally treating chronic pain associated with certain illnesses, treating convulsions or muscular spasms and other health problems such as nausea or lack of appetite.
This company was created in 2009 at Smith Falls in Canada and is now a large scale business with a number of subsidiaries among which we find for example Canopy Health Innovations, Mettrum Health Corporation, BC Tweed Joint Venture, Spot Therapeutics, HEMPCA, Tokyo Smoke, Annabis Medical, Spectrum Cannabis Chile, Spectrum Chile, Tweed, Bedrocan Cannabis Corp, Daddy Can Lesotho PTY, Spectrum Cannabis Denmark, Prime1 Construction Services, Tweed Farms, Vert Medical, Canopy LATAM, MedCann Gmbh, Trees Producers Limited and Tweed Grasslands Cannabis Inc.Through all these subsidiaries Canopy Growth employs over 1,030 people around the world.
The Canopy Growth group is also known as being the first company in this activity sector in North America to have been introduced onto the stock markets.This group is in fact included in the S&P/TSX stock market index.
Know the competition to Canopy Growth shares:
The Canadian group Canopy Growth is undoubtedly one of the rarest companies of this size exercising activities in the therapeutic cannabis sector. However, it is not the only company to target this new market sector and the legalisation of this type of treatment is increasing in range progressively throughout the world.The competitors of Canopy Growth are few at present but it is important you know about them if you wish to speculate in this asset on the stock markets.
Recently, the medical cannabis market has experienced a major change as until recently Canopy Growth was the leader in this sector, followed by the Aurora Group, then CanniMed.However in January 2018 the Aurora Group completed the buyout of CanniMed creating a new company named Aurora Cannabis.It is currently this new company that is the largest therapeutic cannabis producer worldwide.
Tilray Inc.: This is another Canadian company that is currently achieving great success in the medical and therapeutic cannabis sectors and which is also developing a range of products manufactured from hemp. It is therefore recommended that you take this company into account when analysing the competitors of the Canopy Growth Company.
The strategic alliances implemented by the Canopy Growth group:
Over the last few years the Canopy Growth Company has heavily invested in the implementation of strategic partnerships with various companies in similar or complementary sectors.This has enabled the company to enlarge its field of activities as well as gain position in new markets and highly advantageous contracts.To better understand the benefits of this type of alliance we offer you the opportunity to learn about some of the more recent ones here together with their objectives.
- Alcaliber: In September 2017, Canopy Growth completed a strategic alliance with the Spanish company Alcaliber authorising the latter to produce cannabis cultivars supplied by the Canadian company to sell in their country.In 2018 the first delivery of 1,500 of these cannabis plant clones was completed between the two companies.
- Société des alcools du Québec: In April 2018, Canopy Growth signed a partnership agreement with the company Société des alcools du Québec relating to a three year supply agreement for over 12,000 kg of high quality cannabis.This alliance came about just after the province of Quebec issued an announcement of the forthcoming legalisation of recreational cannabis in the country.
- Centric Health: Finally, more recently, in September 2018 to be more exact, Canopy Growth implemented a strategic partnership with the company Centric Health relating to supply and services.This contract related to the supply of medical cannabis from Canopy Growth to Centric Health.Canopy Growth, through its brand Spectrum Cannabis, would thereby become the favoured partner in terms of training and the major supplier to this health company for a variety of products related to the culture of medical cannabis.These products would then be used in long term health care or in care homes for the elderly.
The advantages and strong points of the Canopy Growth shares as stock market assets:
- Firstly, the position of Canopy Growth on the therapeutic cannabis market is undoubtedly one of its major advantages.Let us remember that this group is in fact in second position of this market worldwide just behind its principal competitor Aurora Cannabis.
- The weak level of competition in this activity sector is a second strong point for the Canopy Growth group as the small producers which are the most numerous do not represent a serious threat to this much larger company.
- The eagerness of Canopy Growth to diversify its activities by positioning itself in advance in the recreational cannabis sector is also a major advantage that should enable it to considerably increase its revenue in the coming years as many countries and areas, including Quebec, seem eager to embrace the legalisation of this type of product.
- We also appreciate the efforts made by this company in order to gain parts of the market and widen its activities throughout the world.This notably takes place through the implementation of targeted partnerships and strategic alliances notably in Europe.
- Finally, the group management demonstrates a real transparency regarding its development and growth strategies implemented and communicated clearly relating to its objectives.This has of course had the effect of reassuring investors and shareholders.
The disadvantages and weak points of Canopy Growth shares as stock market assets:
- Firstly, even though the future development prospects of this company’s activities appear attractive it should be noted that the financial results of Canopy Growth are up to now unsatisfactory, in fact the company is running more at a loss.Of course, this is seen as a temporary situation due to the strategies implemented by this company and this should be rapidly overcome.However, it does have the consequence of worrying a certain part of the market as long as positive results are not seen.
- On the other hand it should be remembered that the medical cannabis market, like that of the recreational cannabis, is subject to regulations that vary according to the different countries.These regulations can be a real setback to the activities of Canopy Growth and its future profitability.It is therefore important to monitor events and news.
- Finally, the recent development of activities of the major competitor of Canopy Growth, Aurora Cannabis, following the buyout of Cannimed, represents of course a significant threat to the previous market leader which has seen it lose its number one position in the cannabis sector worldwide.Over the long term this could negatively affect sales and the signature of large new contracts.
To summarise, even if the disadvantages of the Canopy Growth Company appear less numerous than the advantages it is still necessary for every serious investor to take them into account when completing analyses and not just launch a buying strategy without reflection.